Table 2.
Associations between HLA class II and six AIDs: SLE, Ps + PsA, RA, SSc, MS, and MG.
| Controls (n = 282) |
SLE (n = 213) |
Ps + PsA (n = 166) |
RA (n = 153) |
SSc (n = 67) |
MS (n = 536) |
MG (n = 93) |
Total (n = 1228) |
|
|---|---|---|---|---|---|---|---|---|
| HLA-DRB1∗01 | 66 (23.4%) | 40 (18.8%) | 39 (23.5%) |
50 (32.7%)
OR = 1.79 p = 0.017 |
28 (41.8%)
OR = 2.28 p = 0.006 |
100 (18.7%) | 23 (24.7%) | 280 (22.8%) |
|
| ||||||||
| HLA-DRB1∗03 | 44 (15.6%) |
73 (34.3%)
OR = 2.49 p = 4.2 × 10 −5 |
25 (15.1%) | 28 (18.3%) | 11 (16.4%) |
123 (22.9%)
OR = 1.81 p = 0.003 |
33 (35.5%)
OR = 2.98 p = 6.1 × 10 −5 |
293 (23.9%)
OR = 1.51 p = 0.022 |
|
| ||||||||
| HLA-DRB1∗04 | 69 (24.5%) | 42 (19.7%) | 46 (27.7%) |
73 (47.7%)
OR = 2.81 p = 6 × 10 −6 |
13 (19.4%) | 128 (23.9%) | 23 (24.7%) | 325 (26.5%) |
|
| ||||||||
| HLA-DRB1∗07 | 72 (25.5%) | 55 (25.8%) |
66 (39.8%)
OR = 1.79 p = 0.006 |
38 (24.8%) | 14 (20.9%) | 147 (27.4%) | 23 (24.7%) | 343 (27.9%) |
|
| ||||||||
| HLA-DRB1∗08 | 24 (8.5%) | 21 (10.0%) | 10 (6.0%) |
3 (2.0%)
OR = 0.24 p = 0.026 |
15 (22.4%)
OR = 3.01 p = 0.004 |
65 (12.1%)
OR = 1.73 p = 0.033 |
7 (7.5%) | 121 (9.9%) |
|
| ||||||||
| HLA-DRB1∗09 | 14 (5.0%) |
2 (1.0%)
OR = 0.18 p = 0.027 |
5 (3.0%) |
0 (0.0%)
∗
OR = 0.95 p = 0.003 |
3 (4.5%) |
5 (1.0%)
OR = 0.22 p = 0.004 |
2 (2.2%) |
17 (1.4%)
OR = 0.23 p = 1 × 10 −4 |
|
| ||||||||
| HLA-DRB1∗13 | 84 (29.8%) |
39 (18.3%)
OR = 0.58 p = 0.016 |
32 (19.3%)
OR = 0.62 p = 0.050 |
25 (16.3%)
OR = 0.58 p = 0.044 |
8 (11.9%)
OR = 0.42 p = 0.035 |
124 (23.1%) | 17 (18.3%) |
245 (20.0%)
OR = 0.58 p = 0.004 |
|
| ||||||||
| HLA-DRB1∗15 | 56 (19.9%) | 55 (25.8%) | 22 (13.3%) | 17 (11.1%) | 12 (17.9%) |
175 (32.7%)
OR = 2.17 p = 2 × 10 −5 |
15 (16.1%) | 296 (24.1%) |
AIDs: autoimmune diseases; SLE: Systemic Lupus Erythematosus; Ps + PsA: Psoriasis or Psoriatic Arthritis; RA: Rheumatoid Arthritis; SSc: Systemic Sclerosis; MS: Multiple Sclerosis; MG: Myasthenia Gravis. ∗Fisher's exact test was used to calculate this value.